2026-04-01 20:05:14
Design Therapeutics Appoints Dr. David Shapiro to Board of Directors
Expected Stock impact: Slightly Positive
On April 1, 2026, Design Therapeutics, Inc. announced the appointment of Dr. David Shapiro, M.D., to its Board of Directors as a Class III director. This appointment is effective immediately and will last until the company's annual meeting of stockholders in 2027. Dr. Shapiro's addition to the board is expected to enhance the company's governance and strategic direction. He will also serve on the Nominating and Corporate Governance Committee. As part of the company's non-employee director compensation policy, Dr. Shapiro will receive an annual cash retainer of $40,000 for his service on the Board and an additional $5,000 for his role on the Nominating Committee. Furthermore, he has been granted an initial option to purchase 60,000 shares of common stock, which will vest monthly over a three-year period, along with a prorated annual option grant to purchase 7,500 shares, vesting monthly over one year. This strategic move is anticipated to positively impact the company's governance and operational execution, aligning with its long-term growth objectives. The company has also entered into a standard indemnification agreement with Dr. Shapiro, ensuring protection for him as a director. This appointment reflects Design Therapeutics' commitment to strengthening its leadership team and enhancing its strategic capabilities in the biopharmaceutical sector.
